Beijing Pharmaceutical Investment And Management (bvi) Limited - Net Worth and Insider Trading

Beijing Pharmaceutical Investment And Management (bvi) Limited Net Worth

The estimated net worth of Beijing Pharmaceutical Investment And Management (bvi) Limited is at least $132 Million dollars as of 2024-09-29. Beijing Pharmaceutical Investment And Management (bvi) Limited is the 2201 Interest of corporation controlled by you of Immunotech Biopharm Ltd and owns about 51,458,400 shares of Immunotech Biopharm Ltd (HKSE:06978) stock worth over $132 Million. Details can be seen in Beijing Pharmaceutical Investment And Management (bvi) Limited's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Beijing Pharmaceutical Investment And Management (bvi) Limited has not made any transactions after 2021-07-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Beijing Pharmaceutical Investment And Management (bvi) Limited

Beijing Pharmaceutical Investment And Management (bvi) Limited Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Beijing Pharmaceutical Investment And Management (bvi) Limited owns 1 companies in total, including Immunotech Biopharm Ltd (HKSE:06978) .

Click here to see the complete history of Beijing Pharmaceutical Investment And Management (bvi) Limited’s form 4 insider trades.

Insider Ownership Summary of Beijing Pharmaceutical Investment And Management (bvi) Limited

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:06978	Immunotech Biopharm Ltd	2021-07-20	2201 Interest of corporation controlled by you

Beijing Pharmaceutical Investment And Management (bvi) Limited Latest Holdings Summary

Beijing Pharmaceutical Investment And Management (bvi) Limited currently owns a total of 1 stock. Beijing Pharmaceutical Investment And Management (bvi) Limited owns 51,458,400 shares of Immunotech Biopharm Ltd (HKSE:06978) as of July 20, 2021, with a value of $132 Million.

Latest Holdings of Beijing Pharmaceutical Investment And Management (bvi) Limited

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:06978	Immunotech Biopharm Ltd	2021-07-20	51,458,400	2.56	131,733,504

Holding Weightings of Beijing Pharmaceutical Investment And Management (bvi) Limited

Beijing Pharmaceutical Investment And Management (bvi) Limited Form 4 Trading Tracker

According to the SEC Form 4 filings, Beijing Pharmaceutical Investment And Management (bvi) Limited has made a total of 1 transactions in Immunotech Biopharm Ltd (HKSE:06978) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Immunotech Biopharm Ltd is the acquisition of 51,458,400 shares on July 20, 2021, which cost Beijing Pharmaceutical Investment And Management (bvi) Limited around $0.

Insider Trading History of Beijing Pharmaceutical Investment And Management (bvi) Limited

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Beijing Pharmaceutical Investment And Management (bvi) Limited Trading Performance

GuruFocus tracks the stock performance after each of Beijing Pharmaceutical Investment And Management (bvi) Limited's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Beijing Pharmaceutical Investment And Management (bvi) Limited is -14.72%. GuruFocus also compares Beijing Pharmaceutical Investment And Management (bvi) Limited's trading performance to market benchmark return within the same time period. The performance of stocks bought by Beijing Pharmaceutical Investment And Management (bvi) Limited within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Beijing Pharmaceutical Investment And Management (bvi) Limited's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Beijing Pharmaceutical Investment And Management (bvi) Limited

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-18.68
Relative Return to S&P 500(%)	-21.42

Beijing Pharmaceutical Investment And Management (bvi) Limited Ownership Network

Ownership Network List of Beijing Pharmaceutical Investment And Management (bvi) Limited

No Data

Ownership Network Relation of Beijing Pharmaceutical Investment And Management (bvi) Limited

Beijing Pharmaceutical Investment And Management (bvi) Limited Owned Company Details

What does Immunotech Biopharm Ltd do?

Who are the key executives at Immunotech Biopharm Ltd?

Beijing Pharmaceutical Investment And Management (bvi) Limited is the 2201 Interest of corporation controlled by you of Immunotech Biopharm Ltd. Other key executives at Immunotech Biopharm Ltd include Jung Hyun Chul , Evodevo LTD , and 2501 Other tian jin he yue ke ji fa zhan he huo qi ye you xian he huo .

Immunotech Biopharm Ltd (HKSE:06978) Insider Trades Summary

Over the past 18 months, Beijing Pharmaceutical Investment And Management (bvi) Limited made no insider transaction in Immunotech Biopharm Ltd (HKSE:06978). Other recent insider transactions involving Immunotech Biopharm Ltd (HKSE:06978) include a net sale of 0 shares made by tian jin shan zhen ke ji fa zhan he huo qi ye you xian he huo , a net sale of 0 shares made by tian shi li kong gu ji tuan you xian gong si , and a net sale of 0 shares made by Jung Hyun Chul .

In summary, during the past 3 months, insiders sold 0 shares of Immunotech Biopharm Ltd (HKSE:06978) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunotech Biopharm Ltd (HKSE:06978) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immunotech Biopharm Ltd (HKSE:06978)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immunotech Biopharm Ltd Insider Transactions

No Available Data

Beijing Pharmaceutical Investment And Management (bvi) Limited Mailing Address

Above is the net worth, insider trading, and ownership report for Beijing Pharmaceutical Investment And Management (bvi) Limited. Currently GuruFocus does not have mailing address information for Beijing Pharmaceutical Investment And Management (bvi) Limited.

Discussions on Beijing Pharmaceutical Investment And Management (bvi) Limited

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.